Oncology Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.

      Venclyxto logo
      VENCLYXTO CLL PRESCRIBING INFORMATION
      VENCLYXTO GB SUMMARY OF PRODUCT CHARACTERISTICS
      VENCLYXTO NI SUMMARY OF PRODUCT CHARACTERISTICS

      UK-VNCCLL-230491. Date of preparation: February 2024.

       

      FRONTIERS is a programme of AbbVie promotional events and resources for UK HCPs involved in the management of haematological malignancies.

      FRONTIERS comprises a series of in-person, CPD-accredited meetings with agendas devised by an expert clinical steering committee, plus regular online events and on-demand resources providing data updates, congress updates, practice pointers, and expert insights for UK HCPs.
       

      On-Demand Resources

      Front line CLL – the impact of genetic markers on treatment selection

      Dr Othman Al-Sawaf of the German CLL Study Group provides insights on how genetic markers may impact the selection of front-line treatments for patients with CLL.

      Dr Walewska's ASH 2023 Highlights 

      Speaking during the ASH 2023 congress, Dr Renata Walewska (University Hospitals Dorset) expands on fixed-duration venetoclax therapy and treatment sequencing in CLL.

      Fitness for VEN+O

      Dr Nicolas Martinez-Calle (Nottingham University Hospital) describes how a pooled analysis of data from CLL-13 and CLL-14, presented at ASH 2023, highlights that VEN+O may offer a front-line option for CLL patients across different age and fitness groups.1

      Dr Patten's ASH 2023 Highlights

      Dr Piers Patten (King’s College London) describes how long-term follow-up data from CLL-13, a front-line study of VEN+O in CLL, is helping inform treatment decision-making.2

      MURANO – Insights on treatment sequencing & VENCLYXTO retreatment

      Insights from Dr Piers Patten (King’s College London), speaking during ASH 2023, following data updates from the MURANO study relating to treatment sequencing.3

      Fitness for VEN+O as a first-line therapy: Insights from a pooled analysis of CLL-13 and CLL-14

      Speaking during ASH 2023, Dr Piers Patten (King’s College London) describes how the pooled analysis data from the CLL-13 and CLL-14 studies underscores the place for VEN+O in first-line management of CLL.1

      Looking for AML FRONTIERS? Access it here.

       

      UK-VNCCLL-230508. Date of preparation: April 2024.

       

      References

      1. Al-Sawaf O et al. Abstract and Poster 4639. ASH 2023.
      2. Fürstenau M et al. Abstract 635. ASH 2023.
      3. Harrup RA et al. Abstract and Poster 1898. ASH 2023.

       
      You are advised to read the Prescribing Information and Summary of Product Characteristics to evaluate patient suitability for VENCLYXTO.

      VENCLYXTO PRESCRIBING INFORMATION
      VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS (GB)
      VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS (NI)

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.